MedTrace Logo

Safety and Preliminary Efficacy Study of GX-I7 in Patients With COVID-19

NCT04730427 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2022-11-30

No results posted yet for this study

Summary

This study is a phase 1b clinical trial to investigate the safety and preliminary effects of a single dose of a test drug or placebo to the subjects who has diagnosed as COVID-19 infection.

Conditions

  • Covid19

Interventions

DRUG

GX-I7

Recombinant human interleukin-7 hybrid Fc

DRUG

GX-I7 vehicle

Formulation buffer of recombinant human interleukin-7 hybrid Fc

Sponsors & Collaborators

  • Genexine, Inc.

    lead INDUSTRY

Principal Investigators

  • Minkyu Heo · Genexine_Clinical Development Dept.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-24
Primary Completion
2022-05-08
Completion
2022-07-07

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04730427 on ClinicalTrials.gov